140. ドラベ症候群 Dorabe syndrome Clinical trials / Disease details
臨床試験数 : 116 / 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04442295 (ClinicalTrials.gov) | June 3, 2020 | 8/6/2020 | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome | An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome | Dravet Syndrome | Drug: STK-001 - Single Ascending Doses;Drug: STK-001 - Multiple Ascending Doses | Stoke Therapeutics, Inc | NULL | Recruiting | 2 Years | 18 Years | All | 70 | Phase 1/Phase 2 | United States |